Previsão

O preço-alvo médio dos analistas é € 18,20 (+307,16%). A mediana é € 18,20 (+307,16%).

Comprar	13
Manter	5
Vender	1

Notícias Ir para o feed de notícias

Vanda Pharmaceuticals unveils psychiatry growth plan focused on BYSANTI and NEREUS

At the Cantor conference, Vanda presented a growth strategy that expands its commercial portfolio from three to five products and identifies the psychiatry division as the main driver. Management targets a psychiatry revenue potential of $750 million by 2030, assuming approvals, switching rates and payer behavior proceed as planned. Near-term catalysts are BYSANTI (expected improved gross-to-net profile) and the launch of NEREUS with an additional opportunity related to GLP-1‑induced nausea; multiple Phase III readouts are expected in late 2026 to H1 2027. Remaining risks include regulatory hurdles, trial results and reimbursement dynamics. » Mais em de.investing.com
EU grants Vanda orphan drug status for imsidolimab in generalized pustular psoriasis

The European Commission has granted orphan drug status to Vanda’s investigational treatment imsidolimab for generalized pustular psoriasis (GPP), based on a recommendation from the EMA’s committee for rare diseases. It is the first agent to receive this designation for GPP in the EU; the FDA and Japan had previously awarded orphan status. The FDA is currently reviewing the biologics license application for imsidolimab, with a target decision date of December 12, 2026. Vanda holds an exclusive worldwide license; regulatory and patent exclusivity are expected into the late 2030s, along with benefits such as scientific advice, reduced fees, and market exclusivity. » Mais em de.investing.com
Vanda misses Q2 forecasts and reports significantly higher loss

Vanda reported an adjusted loss of $1.04 per share in the second quarter versus the $0.60 expected and revenue of $50.5 million (expectation $61.8 million). Strong prescription growth for Fanapt and moderate growth for PONVORY could not offset a sharp decline in HETLIOZ due to generic competition. Operating expenses rose markedly, the net loss widened to $62.5 million, and cash on hand stood at $170 million as of June 30. Vanda reconfirmed its full-year revenue guidance of $240–290 million, expects costs to decline from late 2026/2027, and pointed to several upcoming Phase III milestones and a PDUFA date in December 2026. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Vanda Pharmaceuticals registou receitas de € 44,27 mi e um ganho líquido de -€ 54,77 mi

(EUR)	junho de 2026	YoY
Receitas	44,27 mi	0,77%
Ganho bruto	41,15 mi	0,84%
Ganho líquido	-54,77 mi	137,29%
EBITDA	-55,42 mi	98,72%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 268,35 mi
Número de ações	60,14 mi
Máximo/mínimo de 52 semanas	€ 8,61 - € 3,70
Dividendos	Não
Beta	0,65
PER (PE Ratio)	-1,11
PEG (PEG Ratio)	0,01
P/VC (PB Ratio)	1,41
P/V (PS Ratio)	1,44

Perfil da empresa

Vanda Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von Therapien konzentriert, die einen hohen ungedeckten medizinischen Bedarf decken. Zu den vermarkteten Produkten des Unternehmens gehören HETLIOZ zur Behandlung von Schlaf-Wach-Störungen, die nicht über 24 Stunden andauern, und Fanapt Tabletten zur Behandlung von Schizophrenie. Zu den in der Entwicklung befindlichen Produkten gehören HETLIOZ (Tasimelteon) zur Behandlung von Jetlag-Störungen, Smith-Magenis-Syndrom, pädiatrischem Non-24, Autismus-Spektrum und verzögerter Schlafphasenstörung; Fanapt (Iloperidon) zur Behandlung von bipolaren Störungen und ein Programm für eine lang wirkende injizierbare Formulierung zur Behandlung von Schizophrenie; und Tradipitant (VLY-686), ein niedermolekularer Neurokinin-1-Rezeptor (NK-1R)-Antagonist, zur Behandlung von atopischer Dermatitis, Gastroparese und Reisekrankheit. Zu den in der Entwicklung befindlichen Produkten des Unternehmens gehören auch VTR-297, ein niedermolekularer Histon-Deacetylase-Inhibitor zur Behandlung von hämatologischen Malignomen und mit potenzieller Verwendung zur Behandlung verschiedener onkologischer Indikationen; VQW-765, ein niedermolekularer partieller Agonist des nikotinischen Acetylcholinrezeptors zur Behandlung psychiatrischer Störungen; ein Portfolio von Aktivatoren und Inhibitoren des Mukoviszidose-Transmembranleitfähigkeitsregulators zur Behandlung von trockenen Augen und Augenentzündungen sowie BPO-27 zur Behandlung von sekretorischen Durchfallerkrankungen, einschließlich Cholera, und VHX-896, der aktive Metabolit von Iloperidon. Das Unternehmen vertreibt seine Produkte in den Vereinigten Staaten, Europa und Israel. Vanda Pharmaceuticals Inc. wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Washington, District of Columbia.

Nome	Vanda Pharmaceuticals
CEO	Mihael H. Polymeropoulos
Sede	Washington, dc EUA
Site	vandapharma.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	12/04/2006
Colaboradores	533